CA2290788A1 - Traitement de la dependance a certaines substances a l'aide de composes d'antagonistes d'opiaces et de serotonine - Google Patents
Traitement de la dependance a certaines substances a l'aide de composes d'antagonistes d'opiaces et de serotonine Download PDFInfo
- Publication number
- CA2290788A1 CA2290788A1 CA002290788A CA2290788A CA2290788A1 CA 2290788 A1 CA2290788 A1 CA 2290788A1 CA 002290788 A CA002290788 A CA 002290788A CA 2290788 A CA2290788 A CA 2290788A CA 2290788 A1 CA2290788 A1 CA 2290788A1
- Authority
- CA
- Canada
- Prior art keywords
- person
- naltrexone
- treatment
- alcohol
- opioid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003401 opiate antagonist Substances 0.000 title claims abstract description 33
- 238000011282 treatment Methods 0.000 title claims description 47
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical class C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 title claims description 34
- 208000011117 substance-related disease Diseases 0.000 title claims description 16
- 201000006152 substance dependence Diseases 0.000 title description 5
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims abstract description 57
- 229960003086 naltrexone Drugs 0.000 claims abstract description 56
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 46
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims abstract description 40
- 239000003814 drug Substances 0.000 claims abstract description 30
- 229940079593 drug Drugs 0.000 claims abstract description 28
- 229960002073 sertraline Drugs 0.000 claims abstract description 21
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims abstract description 21
- 229960003920 cocaine Drugs 0.000 claims abstract description 20
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims abstract description 15
- 244000025254 Cannabis sativa Species 0.000 claims abstract description 15
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 claims abstract description 15
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 claims abstract description 15
- 229960002464 fluoxetine Drugs 0.000 claims abstract description 15
- 230000000694 effects Effects 0.000 claims abstract description 14
- 239000000203 mixture Substances 0.000 claims abstract description 12
- 229960004038 fluvoxamine Drugs 0.000 claims abstract description 10
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 claims abstract description 10
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 claims abstract description 9
- 229960004127 naloxone Drugs 0.000 claims abstract description 9
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims abstract description 8
- WJBLNOPPDWQMCH-MBPVOVBZSA-N Nalmefene Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 WJBLNOPPDWQMCH-MBPVOVBZSA-N 0.000 claims abstract description 8
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229960005297 nalmefene Drugs 0.000 claims abstract description 8
- 229960002296 paroxetine Drugs 0.000 claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 25
- 208000007848 Alcoholism Diseases 0.000 claims description 24
- 201000009032 substance abuse Diseases 0.000 claims description 22
- 201000007930 alcohol dependence Diseases 0.000 claims description 20
- 229940076279 serotonin Drugs 0.000 claims description 15
- 231100000736 substance abuse Toxicity 0.000 claims description 10
- 208000022497 Cocaine-Related disease Diseases 0.000 claims description 9
- DBGIVFWFUFKIQN-VIFPVBQESA-N (+)-Fenfluramine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 229960004597 dexfenfluramine Drugs 0.000 claims description 7
- 229960002791 zimeldine Drugs 0.000 claims description 7
- OYPPVKRFBIWMSX-SXGWCWSVSA-N zimeldine Chemical compound C=1C=CN=CC=1C(=C/CN(C)C)\C1=CC=C(Br)C=C1 OYPPVKRFBIWMSX-SXGWCWSVSA-N 0.000 claims description 7
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 claims description 6
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 claims description 6
- 208000003863 Marijuana Abuse Diseases 0.000 claims description 6
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 claims description 6
- 229960002495 buspirone Drugs 0.000 claims description 6
- 201000001843 cannabis dependence Diseases 0.000 claims description 6
- 229960001653 citalopram Drugs 0.000 claims description 6
- 229960001582 fenfluramine Drugs 0.000 claims description 6
- 229950006360 viqualine Drugs 0.000 claims description 6
- XFXANHWIBFMEOY-JKSUJKDBSA-N viqualine Chemical compound C12=CC(OC)=CC=C2N=CC=C1CCC[C@@H]1CCNC[C@@H]1C=C XFXANHWIBFMEOY-JKSUJKDBSA-N 0.000 claims description 6
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 claims description 5
- QOIGKGMMAGJZNZ-UHFFFAOYSA-N gepirone Chemical compound O=C1CC(C)(C)CC(=O)N1CCCCN1CCN(C=2N=CC=CN=2)CC1 QOIGKGMMAGJZNZ-UHFFFAOYSA-N 0.000 claims description 5
- 229960000647 gepirone Drugs 0.000 claims description 5
- 229960005343 ondansetron Drugs 0.000 claims description 5
- 235000019788 craving Nutrition 0.000 claims description 3
- 206010013663 drug dependence Diseases 0.000 claims description 3
- 230000014759 maintenance of location Effects 0.000 claims description 3
- 201000006145 cocaine dependence Diseases 0.000 claims description 2
- 230000004044 response Effects 0.000 claims description 2
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 claims 4
- 229940009065 wellbutrin Drugs 0.000 claims 4
- 230000000862 serotonergic effect Effects 0.000 abstract description 25
- 229940127240 opiate Drugs 0.000 abstract description 14
- 238000001784 detoxification Methods 0.000 abstract description 8
- 230000007423 decrease Effects 0.000 abstract description 4
- FELGMEQIXOGIFQ-UHFFFAOYSA-N Ondansetron Chemical compound CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-UHFFFAOYSA-N 0.000 abstract description 3
- 230000001419 dependent effect Effects 0.000 description 15
- 230000035622 drinking Effects 0.000 description 12
- 235000021271 drinking Nutrition 0.000 description 12
- 239000003887 narcotic antagonist Substances 0.000 description 12
- 238000002483 medication Methods 0.000 description 9
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 8
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 8
- 229960004242 dronabinol Drugs 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 206010013654 Drug abuse Diseases 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 201000001272 cocaine abuse Diseases 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 208000026251 Opioid-Related disease Diseases 0.000 description 5
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 5
- 230000002787 reinforcement Effects 0.000 description 5
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 4
- 206010001584 alcohol abuse Diseases 0.000 description 4
- 208000025746 alcohol use disease Diseases 0.000 description 4
- 208000029650 alcohol withdrawal Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 229960001797 methadone Drugs 0.000 description 4
- 238000007910 systemic administration Methods 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 3
- 201000009322 cannabis abuse Diseases 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 229960003638 dopamine Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 201000005040 opiate dependence Diseases 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000003762 serotonin receptor affecting agent Substances 0.000 description 3
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 206010012335 Dependence Diseases 0.000 description 2
- 208000005565 Marijuana Use Diseases 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 206010048010 Withdrawal syndrome Diseases 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- -1 citralopram Chemical compound 0.000 description 2
- 238000009223 counseling Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229960005181 morphine Drugs 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 238000001050 pharmacotherapy Methods 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 230000003014 reinforcing effect Effects 0.000 description 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- UZHSEJADLWPNLE-OGLQFSJHSA-N (4R,4aS,12bS)-4a,9-dihydroxy-3-prop-2-enyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one Chemical compound O1C2C(=O)CC[C@@]3(O)[C@]4([H])N(CC=C)CC[C@]23C2=C1C(O)=CC=C2C4 UZHSEJADLWPNLE-OGLQFSJHSA-N 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 206010053164 Alcohol withdrawal syndrome Diseases 0.000 description 1
- 241000218236 Cannabis Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 206010054089 Depressive symptom Diseases 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- 206010049976 Impatience Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 102000001490 Opioid Peptides Human genes 0.000 description 1
- 108010093625 Opioid Peptides Proteins 0.000 description 1
- 102000003840 Opioid Receptors Human genes 0.000 description 1
- 108090000137 Opioid Receptors Proteins 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038678 Respiratory depression Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003502 anti-nociceptive effect Effects 0.000 description 1
- 239000003420 antiserotonin agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- 229960002563 disulfiram Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000006742 locomotor activity Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000003402 opiate agonist Substances 0.000 description 1
- 239000003399 opiate peptide Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000001671 psychotherapy Methods 0.000 description 1
- 229940110294 revia Drugs 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 description 1
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Addiction (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
L'invention porte sur un traitement de la dépendance de patients vis à vis de l'alcool, de la marijuana, de la cocaïne, des opiacés, consistant à leur administrer une combinaison d'une quantité efficace d'un antagoniste des opiacés tel que la nalméfène, la naloxone, la naltréxone ou un de leurs mélanges, et une médication sérotonergique de sertraline, de fluoxétine, de paroxétine, de fluvoxamine ou d'odansétron. L'administration d'une quantité efficace d'un antagoniste des opiacés seule aide à prévenir les rechutes une fois la désintoxication achevée, tandis que l'adjonction de la médication sérotonergique accroît l'efficacité des antagonistes des opiacés, tout en en réduisant les effets secondaires et en contribuant à atténuer les effets du sevrage.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4616297P | 1997-05-20 | 1997-05-20 | |
| US60/046,162 | 1997-05-20 | ||
| PCT/US1998/010289 WO1998052565A1 (fr) | 1997-05-20 | 1998-05-19 | Traitement de la dependance a certaines substances a l'aide de composes d'antagonistes d'opiaces et de serotonine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2290788A1 true CA2290788A1 (fr) | 1998-11-26 |
Family
ID=21941947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002290788A Abandoned CA2290788A1 (fr) | 1997-05-20 | 1998-05-19 | Traitement de la dependance a certaines substances a l'aide de composes d'antagonistes d'opiaces et de serotonine |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1011671A1 (fr) |
| JP (1) | JP2002508753A (fr) |
| AU (1) | AU7582498A (fr) |
| CA (1) | CA2290788A1 (fr) |
| WO (1) | WO1998052565A1 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6454789B1 (en) | 1999-01-15 | 2002-09-24 | Light Science Corporation | Patient portable device for photodynamic therapy |
| US6306425B1 (en) * | 1999-04-09 | 2001-10-23 | Southern Research Institute | Injectable naltrexone microsphere compositions and their use in reducing consumption of heroin and alcohol |
| US20010049375A1 (en) * | 2000-03-15 | 2001-12-06 | Wolfgang Sadee | Neutral antagonists and use thereof in treating drug abuse |
| EP1602374A4 (fr) * | 2003-03-07 | 2007-03-07 | Toray Industries | Medicament contre la dependance aux drogues et aux substances toxiques |
| RU2428984C1 (ru) * | 2010-05-24 | 2011-09-20 | Общество с ограниченной ответственностью "Урал Крафт" | Способ купирования алкогольной абстиненции |
| WO2014120936A2 (fr) | 2013-01-30 | 2014-08-07 | Pharmorx Therapeutics, Inc. | Traitement de la dépression et autres maladies avec un agent à faible dose |
| MX2016013889A (es) | 2014-04-22 | 2017-03-09 | Otsuka Pharma Co Ltd | Medicamento. |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5114976A (en) * | 1989-01-06 | 1992-05-19 | Norden Michael J | Method for treating certain psychiatric disorders and certain psychiatric symptoms |
| US5486362A (en) * | 1991-05-07 | 1996-01-23 | Dynagen, Inc. | Controlled, sustained release delivery system for treating drug dependency |
-
1998
- 1998-05-19 CA CA002290788A patent/CA2290788A1/fr not_active Abandoned
- 1998-05-19 WO PCT/US1998/010289 patent/WO1998052565A1/fr not_active Ceased
- 1998-05-19 AU AU75824/98A patent/AU7582498A/en not_active Abandoned
- 1998-05-19 EP EP98923558A patent/EP1011671A1/fr not_active Withdrawn
- 1998-05-19 JP JP55056398A patent/JP2002508753A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2002508753A (ja) | 2002-03-19 |
| AU7582498A (en) | 1998-12-11 |
| WO1998052565A1 (fr) | 1998-11-26 |
| EP1011671A1 (fr) | 2000-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2492858C2 (ru) | Композиции и способы профилактики и лечения зависимостей | |
| EP0687175B1 (fr) | Procede de traitement de maladie emotionnelle ou mentale, et maladie emotionnelle ou mentale concomitante a des crises | |
| Kleber | Pharmacologic treatments for heroin and cocaine dependence | |
| Warner et al. | Pharmacotherapy for opioid and cocaine abuse | |
| Ye et al. | Ondansetron: a selective 5‐HT3 receptor antagonist and its applications in CNS‐related disorders | |
| Wikler | Opioid dependence: Mechanisms and treatment | |
| US6004970A (en) | Smoking cessation treatments using naltrexone and related compounds | |
| MX2007012355A (es) | Metodos para el tratamiento de abuso y dependencia de sustancia. | |
| CN1413111A (zh) | 右美沙芬和氧化酶抑制剂使患者摆脱麻醉药和抗抑郁药的用途 | |
| KR20020081271A (ko) | 물질 남용의 치료 방법 | |
| Guthrie | Pharmacologic interventions for the treatment of opioid dependence and withdrawal | |
| CA2290788A1 (fr) | Traitement de la dependance a certaines substances a l'aide de composes d'antagonistes d'opiaces et de serotonine | |
| Sim | Methadone | |
| AU672772B2 (en) | Alleviating or prevention of migraine headache onset with mast cell degranulation blocking agents | |
| EP1347778B1 (fr) | Chimiotherapie de comportement | |
| Singh et al. | Opioid antagonists. I: Pharmacology and rationale for use in treating self-injury | |
| US12533325B2 (en) | Composition and method for preventing or treating opioid withdrawal symptoms | |
| Schifano | Drug abuse: treatment and management | |
| Rénéric et al. | Opioid receptor antagonists in psychiatry: Beyond drug addiction | |
| Kampman | Biologic Treatments for Drug and Alcohol Dependence. | |
| KLEBER | Detoxification from Methadone Maintenance: Current and Innovative | |
| Kleber | Detoxification from Methadone Maintenance: Current and Innovative Approaches | |
| Preda et al. | Opioid abuse | |
| Ey | Naltrexone hydrochloride use in the treatment of alcoholism | |
| Giannini et al. | P's and blues: potentiation of propoxyphene withdrawal by a variety of antihistamines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |